Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year
Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments
Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance
Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an award-winning study on GLP-1 users with diabetic gastroparesis at ACG 2024
Conference call and webcast to be held today at 4:30 p.m. ET
SOLANA BEACH, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update.
“2024 was a transformative year for Evoke Pharma, as we successfully executed on key commercial and strategic initiatives that drove strong revenue growth, expanded patient access to GIMOTI, and reinforced our leadership position in the gastroparesis treatment market,” said Matt D’Onofrio, Chief Executive Officer of Evoke Pharma. “Our revenue nearly doubled year-over-year, reaching $10.2 million, and we exceeded our previous guidance while achieving significant growth across key commercial metrics. The transition to ASPN Pharmacies played a crucial role in these results, significantly improving prescription fulfillment rates and patient access. Additionally, our award-winning data presentation at ACG 2024 underscored GIMOTI’s clinical utility, particularly for GLP-1 users with diabetic gastroparesis.”
Fourth Quarter and Full Year 2024 Developments and Recent Highlights:
Revenue Growth and Market Expansion
Stronger Financial Position
Clinical Validation and Awareness
Competitive Positioning and Market Exclusivity
“Looking ahead to 2025, we remain focused on expanding pharmacy partnerships to further improve patient access to GIMOTI. Our anticipated increased budget allocation from EVERSANA will support enhanced commercialization efforts, including the hiring of field reimbursement managers to help healthcare providers navigate payer policies and streamline patient access to GIMOTI. Additionally, we will continue generating and presenting new data while strategically engaging the gastroenterology community to further solidify GIMOTI’s role as the standard of care for diabetic gastroparesis.,” Mr. D'Onofrio concluded.
Fourth Quarter and Full Year 2024 Financial Review and Outlook
For the fourth quarter of 2024, net product sales were approximately $3.3 million compared with $1.7 million during the fourth quarter of 2023, and the net loss was approximately $1.2 million, or $0.49 per share compared with $2.0 million, or $7.13 per share, for the fourth quarter of 2023. For the year ended December 31, 2024, net product sales were approximately $10.2 million compared with approximately $5.2 million for the year ended December 31, 2023, and the net loss was approximately $5.4 million, or $2.81 per share, compared with a net loss of $7.8 million, or $27.97 per share, for the year ended December 31, 2023. The year-over-increase in revenue was due to significantly higher net product sales in 2024, resulting from:
There were no research and development expenses incurred during the fourth quarter of 2024 compared with $23,000 for the fourth quarter of 2023. For the full year of 2024, research and development expenses were approximately $16,000 compared with approximately $0.2 million for the prior year.
For the fourth quarter of 2024, selling, general and administrative (SG&A) expenses were approximately $4.4 million compared with $3.5 million for the fourth quarter of 2023. For the year ended December 31, 2024, selling, general and administrative expenses were approximately $15.1 million versus approximately $12.2 million for the year ended December 31, 2023. The increase in SG&A costs year-over-year resulted primarily from higher marketing and Eversana profit sharing costs. We expect that selling, general and administrative expenses will increase in the future as we continue to progress with the commercialization of GIMOTI.
Total operating expenses for the fourth quarter of 2024 were approximately $4.5 million compared with $3.6 million for the same period of 2023. For the year ended December 31, 2024, total operating expenses were approximately $15.5 million compared with approximately $12.6 million for the full year of 2023.
As of December 31, 2024, cash and cash equivalents were approximately $13.6 million. We anticipate that based on our current and expanded operating and commercial plans, that our existing cash and cash equivalents along with the $14.3 million raised through equity financings in 2024, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the first quarter of 2026.
Also, as of December 31, 2024, and the two preceding quarters, the company remained in compliance with Nasdaq’s minimum stockholder’s equity requirement.
Evoke projects net revenue in 2025 of approximately $16 million, an approximate 60% increase from 2024 net revenue. Evoke’s 2025 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.
Conference Call and Webcast
Evoke’s management team will host a conference call today at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800)-267-6316 and 203-518-9783 for international callers. The conference ID is EVOKQ424. A live webcast can also be accessed under events on the company’s investor relations page.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow GIMOTI on Facebook
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
About Gimoti® (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information
WARNING: TARDIVE DYSKINESIA
GIMOTI is not recommended for use in:
GIMOTI is contraindicated:
Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥5%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2025 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, including the potential that GIMOTI could become the standard of care for gastroparesis; the potential for additional funds from the exercise of outstanding warrants and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2025 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
Financial Statements to Follow
Evoke Pharma, Inc. Balance Sheets | |||||||
December 31, | |||||||
2024 | 2023 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 13,596,600 | $ | 4,739,426 | |||
Accounts receivable, net of allowance for credit losses of $0 | 2,420,373 | 673,071 | |||||
Prepaid expenses | 731,945 | 885,040 | |||||
Inventories | 445,081 | 481,840 | |||||
Other current assets | 43,898 | 47,532 | |||||
Total current assets | 17,237,897 | 6,826,909 | |||||
Operating lease right-of-use asset | 154,184 | — | |||||
Deferred offering costs | 120,614 | 241,637 | |||||
Other long-term assets | 6,312 | — | |||||
Total assets | $ | 17,519,007 | $ | 7,068,546 | |||
Liabilities and stockholdersʼ equity (deficit) | |||||||
Current liabilities: | |||||||
Accounts payable and accrued expenses | $ | 2,341,191 | $ | 1,711,778 | |||
Accrued compensation | 865,650 | 1,324,010 | |||||
Operating lease liability | 59,533 | — | |||||
Note payable | 5,000,000 | 5,000,000 | |||||
Accrued interest payable | 2,113,665 | 1,612,295 | |||||
Total current liabilities | 10,380,039 | 9,648,083 | |||||
Operating lease liability, net of current portion | 100,958 | — | |||||
Total liabilities | 10,480,997 | 9,648,083 | |||||
Commitments and contingencies | |||||||
Stockholdersʼ equity (deficit): | |||||||
Preferred stock, $0.0001 par value; authorized shares — 5,000,000 as of December 31, 2024 and December 31, 2023; issued and outstanding shares — zero as of December 31, 2024 and December 31, 2023 | — | — | |||||
Common stock, $0.0001 par value; authorized shares — 100,000,000 and 50,000,000 as of December 31, 2024 and December 31, 2023, respectively; issued and outstanding shares — 1,486,009 and 278,558 as of December 31, 2024 and December 31, 2023, respectively | 149 | 28 | |||||
Additional paid-in capital | 135,829,493 | 120,859,873 | |||||
Accumulated deficit | (128,791,632 | ) | (123,439,438 | ) | |||
Total stockholdersʼ equity (deficit) | 7,038,010 | (2,579,537 | ) | ||||
Total liabilities and stockholdersʼ equity (deficit) | $ | 17,519,007 | $ | 7,068,546 | |||
Evoke Pharma, Inc. Statements of Operations | |||||||
Year Ended December 31, | |||||||
2024 | 2023 | ||||||
Net product sales | $ | 10,249,415 | $ | 5,180,630 | |||
Operating expenses: | |||||||
Cost of goods sold | 356,531 | 201,879 | |||||
Research and development | 16,322 | 181,907 | |||||
Selling, general and administrative | 15,080,699 | 12,227,735 | |||||
Total operating expenses | 15,453,552 | 12,611,521 | |||||
Loss from operations | (5,204,137 | ) | (7,430,891 | ) | |||
Other income (expense): | |||||||
Interest income | 353,313 | 138,596 | |||||
Interest expense | (501,370 | ) | (500,000 | ) | |||
Total other expense | (148,057 | ) | (361,404 | ) | |||
Net loss | $ | (5,352,194 | ) | $ | (7,792,295 | ) | |
Net loss per share of common stock, basic and diluted | $ | (2.81 | ) | $ | (27.97 | ) | |
Weighted-average shares used to compute basic and diluted net loss per share | 1,905,072 | 278,558 | |||||
Evoke Pharma, Inc. Statements of Cash Flows | |||||||
Year Ended December 31, | |||||||
2024 | 2023 | ||||||
Operating activities | |||||||
Net loss | $ | (5,352,194 | ) | $ | (7,792,295 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Stock-based compensation expense | 773,121 | 1,128,109 | |||||
Non-cash interest expense | 501,370 | 500,000 | |||||
Obsolete inventory adjustment | 3,920 | — | |||||
Non-cash operating lease expense | 12,764 | 129,704 | |||||
Change in operating assets and liabilities: | |||||||
Accounts receivable | (1,747,302 | ) | (48,239 | ) | |||
Prepaid expenses and other assets | 29,803 | 31,932 | |||||
Inventories | 32,839 | (192,462 | ) | ||||
Accounts payable and accrued expenses | 751,754 | 655,126 | |||||
Accrued compensation | (458,360 | ) | 732,852 | ||||
Operating lease liabilities | (6,457 | ) | (129,704 | ) | |||
Net cash used in operating activities | (5,458,742 | ) | (4,984,977 | ) | |||
Financing activities | |||||||
Proceeds from February 2024 Offering | 6,718,211 | — | |||||
Payment of February 2024 Offering costs | (426,292 | ) | (119,296 | ) | |||
Proceeds from March 2024 Warrant Amendment | 1,229,874 | — | |||||
Proceeds from June 2024 Warrant Amendment, net of issuance costs | 308,429 | — | |||||
Proceeds from September 2024 Exercise Price Warrant Amendment, net of issuance costs | 2,532,449 | — | |||||
Proceeds from September 2024 Warrant Amendment, net of issuance costs | 370,622 | — | |||||
Proceeds from exercise of Pre-Funded Warrants, Series A Warrants, Series B Warrants and Series C Warrants | 3,582,814 | — | |||||
Redemption of fractional shares due to reverse stock split | (191 | ) | — | ||||
Net cash provided by (used in) financing activities | 14,315,916 | (119,296 | ) | ||||
Net increase (decrease) in cash and cash equivalents | 8,857,174 | (5,104,273 | ) | ||||
Cash and cash equivalents at beginning of period | 4,739,426 | 9,843,699 | |||||
Cash and cash equivalents at end of period | $ | 13,596,600 | $ | 4,739,426 | |||
Supplemental disclosure of non-cash investing and financing activities | |||||||
February 2024 Offering costs in accounts payable and accrued expenses | $ | — | $ | 122,340 | |||
Operating lease right-of-use asset obtained in exchange for lease liability | $ | 164,253 | $ | — |
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。